Laboratory evidence to support the use of long-term adjuvant tamoxifen therapy for breast cancer.
Animal models all demonstrate that tamoxifen is tumouristatic in the case of breast tumours and long-term or indefinite therapy is required to prevent the appearance of tumours. When treatment is stopped, tumours appear spontaneously or can be encouraged to re-appear with oestrogen therapy. These data support the view that adjuvant clinical trials with tamoxifen should employ a 5- or 10-year treatment regimen.
Jordan
V C
VC
Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison.
D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D051379:Mice; D051381:Rats; D013629:Tamoxifen / Q000627:therapeutic use*
D013629:Tamoxifen